There's a lot of comment here on HC (including mine) about how BLT is worth much more than its current market cap. So, what is a fair value for BLT today?
In round figures, a 1-shot cure for HIV/Aids would be worth north of $2bn, of Hep C probably well north of $7bn (10x the victims of HIV), of Hep B say another $2bn. Ignoring other targets say $11bn in total. Odds against a bio succeeding from PhI/II are generally I think put at around 10:1. So we're down to $1.1bn. But to get there, more cash is needed. Let's assume mgt aren't stupid and that they use a mix of debt and equity and that they wait for efficacy before an IPO. That should see no more than the equivalent of say 50% dilution. So now we're down to $550m. But it's going to take say 2 years before any real earnings, so discounting at say 15%pa, we're down to $415m. Now we need to allow a bit of leeway in the market, say 30%, giving NPV $290m, or share price today 2.47.
Play with those figures how you like, but it seems that BLT right now is a gift at anything much below $2.
Any different ideas, anyone?
- Forums
- ASX - By Stock
- BLT
- Fair value
Fair value
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online